Showing 2680 results
-
Press Release /Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
-
Press Release /Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many…
-
Press Release /Conatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
-
Press Release /For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of…
-
Press Release /New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]…
-
Press Release /Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
-
Press Release /Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
-
Press Release /Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…
-
Key Release /Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both…
-
Press Release /After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11…